Original Article
Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus
N Engl J Med 2007; 356:790-799February 22, 2007
- Abstract
Background
Epidemiologic data suggest that infection with herpes simplex virus type 2 (HSV-2) is associated with increased genital shedding of human immunodeficiency virus type 1 (HIV-1) RNA and HIV-1 transmissibility.
Methods
We conducted a randomized, double-blind, placebo-controlled trial of HSV suppressive therapy with valacyclovir (at a dose of 500 mg twice daily) in Burkina Faso among women who were seropositive for HIV-1 and HSV-2; all were ineligible for highly active antiretroviral therapy. The patients were followed for 24 weeks (12 weeks before and 12 weeks after randomization). Regression models were used to assess the effect of valacyclovir on the presence and quantity of genital and plasma HIV-1 RNA and genital HSV-2 DNA during treatment, adjusting for baseline values, and to evaluate the effect over time.
Results
A total of 140 women were randomly assigned to treatment groups; 136 were included in the analyses. At enrollment, the median CD4 cell count was 446 cells per cubic millimeter, and the mean plasma viral load was 4.44 log10 copies per milliliter. With the use of summary-measures analysis, valacyclovir therapy was found to be associated with a significant decrease in the frequency of genital HIV-1 RNA (odds ratio, 0.41; 95% confidence interval [CI], 0.21 to 0.80) and in the mean quantity of the virus (log10 copies per milliliter, −0.29; 95% CI, −0.44 to −0.15). However, there was no significant decrease in detection of HIV (risk ratio, 0.93; 95% CI, 0.81 to 1.07). HSV suppressive therapy also reduced the mean plasma HIV-1 RNA level by 0.53 log10 copy per milliliter (95% CI, −0.72 to −0.35). Repeated-measures analysis showed that these effects became significantly stronger during the 3 months of follow-up.
Conclusions
HSV suppressive therapy significantly reduces genital and plasma HIV-1 RNA levels in dually infected women. This finding may have important implications for HIV control. (ClinicalTrials.gov number, NCT00158509.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Proportion of Women with Genital HIV-1 RNA According to Visit, Trial Phase, and Study Group.Article Activity
- Article
Epidemiologic and biologic data support a strong association between herpes simplex virus type 2 (HSV-2) and infection with human immunodeficiency virus type 1 (HIV-1).1-5 A recent meta-analysis of prospective observational studies showed that patients who were seropositive for HSV-2 had three times the risk of acquiring HIV-1, as compared with those who were seronegative for the virus.6 In addition, three of four studies showed that HSV-2 infection may increase the quantity of genital HIV-1 RNA.7-10 This association probably arises from both symptomatic11 and asymptomatic genital shedding of HSV-2 DNA, although the evidence for the latter is weaker.12 The biologic plausibility of HSV-2 as a facilitator for genital HIV-1 RNA is supported by various mechanisms, including local influx of activated CD4+ lymphocytes in HSV-infected lesions13 and transactivation of the HIV-1 tat protein and long terminal repeat genes by HSV-2 proteins.14-16 This could result in greater HIV-1 replication at the genital mucosal level and possibly also at the systemic level. In support of the latter hypothesis, symptomatic HSV-2 reactivation has been associated with transient increases in plasma HIV-1 RNA levels17 and acyclovir treatment with reduced plasma HIV-1 RNA levels.18
To establish a relationship between HSV-2 and HIV-1 replication, randomized, controlled trials of HSV-2 control strategies are required.3,19 Our trial, sponsored by the Agence Nationale de Recherches sur le SIDA under grant number 1285 (ANRS 1285), was a randomized, controlled study to determine whether HSV suppressive therapy reduces HIV-1 replication among dually infected women in Bobo-Dioulasso, Burkina Faso.
Patients and Methods
Study Design
We conducted a double-blind, placebo-controlled trial of 500 mg of valacyclovir twice daily for 3 months among women who were dually infected with HIV-1 and HSV-2. None of the women in the study were eligible for highly active antiretroviral therapy (HAART), according to recommendations of the World Health Organization (WHO) for developing countries.20 The study protocol was approved by the institutional review board at Centre Muraz and the ethics committees at the Burkina Faso Ministry of Health and the London School of Hygiene and Tropical Medicine. All patients provided written informed consent.
Patients
Study patients were recruited from the Yerelon cohort of high-risk women described elsewhere,21 from local organizations for people living with HIV/AIDS (PLWHA), and from the University Hospital in Bobo-Dioulasso. Women who were at least 16 years of age, had serum antibodies to both HSV-2 and HIV-1, and were not eligible for HAART could enroll in the study. Exclusion criteria were significant renal impairment (defined as a serum creatinine level of more than twice the normal value) or hypersensitivity to acyclovir; breast-feeding, pregnancy, or a desire to become pregnant in the next 6 months; or a medical indication for HSV suppressive therapy (≥6 clinical episodes per year).
Trial Procedures
At a screening visit, women were informed of the aims and procedures of the trial and were assessed for eligibility. A blood sample was collected from consenting women for serologic tests, CD4 lymphocyte count, and assessment of renal function. Eligible women underwent an informed-consent process and a 1-week reflection period and then entered the baseline phase, which consisted of six visits every other week. At the scheduled sixth visit, eligibility criteria were reassessed, and after collection of appropriate samples, eligible patients were randomly assigned to two groups by means of a 1:1 allocation scheme with block randomization of 10 patients and following a random-allocation list independently provided by the study drug manufacturer. This list was kept by the statistician for the data and safety monitoring committee. Prelabeled, sequentially numbered treatment packs were used; investigators and patients were unaware of study-group assignments. The treatment lasted 12 weeks, with six visits every other week starting 2 weeks after randomization.
At each of the 12 visits, a physician performed a gynecologic examination and collected samples. Menstruating women were deferred for genital sampling until 2 days after bleeding had ceased. During the treatment phase, the physician collected empty drug packs for pill counts, recorded and graded adverse events, counseled patients on compliance and safer-sex measures, and provided condoms.
Women who became pregnant discontinued the study drug but were invited to continue regular follow-up procedures. Women with genital ulcers were initially treated with antibiotics according to national guidelines for the treatment of sexually transmitted infections. After 7 days, nonhealing ulcers were treated with open-label acyclovir (at a dose of 200 mg five times daily for 5 days). The assigned study drug was not discontinued. In addition, both episodic and suppressive therapy with acyclovir remained available to patients after the end of the trial.
Sample Collection
At each visit, swabs were collected for diagnosis of vaginal infections, and cervicovaginal lavage enriched by cervical swabbing was performed for the detection and quantitation of genital HIV-1 RNA and HSV-2 DNA, as previously described.22 At enrollment, additional cervical swabs were collected for the diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis (Amplicor NG/CT, Roche Diagnostics).
Blood samples were drawn on alternate visits for the quantitation of plasma HIV-1. Urine samples were collected before randomization and once a month during the treatment phase for pregnancy testing (Vikia hCG-S, BioMérieux).
Laboratory Analyses
Serologic Assays and CD4+ Analysis
Depending on the source of recruitment, HIV-1 seropositivity was determined with the use of either an enzyme-linked immunosorbent assay (ELISA) or a rapid-testing strategy with Determine (Abbott), followed by Genie II (BioRad), as recommended by the WHO.23 The presence of HSV-2 antibodies was detected by means of a specific IgG2 ELISA (Kalon Biologicals) with high sensitivity and specificity in African serum samples.24 Serologic diagnosis of syphilis was based on positive results on the rapid plasma reagin test (RPR, BioMérieux) and Treponema pallidum hemagglutination assay (TPHA, Newmarket Laboratories). The CD4+ lymphocyte count was performed with a standard fluorocytometry technique (FACScan, Becton Dickinson).
HIV-1 RNA and HSV-2 DNA
HIV-1 RNA and HSV-2 DNA were quantitated by real-time polymerase-chain-reaction assay with the use of the ABI 7000 system and manual nucleic acid extraction (Qiagen RNA and DNA kits), as described previously.22,25,26 Testing of genital HIV-1 RNA was performed in duplicate, and the mean value of the two measures was used in the analyses. The Centre Muraz laboratory participated in an external quality-control program for HIV-1 RNA quantitation organized by ANRS, and the University of Montpellier Virology Laboratory used a commercial panel (HSV 1/2 Clear QC panel, Argene) as an internal quality control for HSV-2 DNA quantitation.
Vaginal Infections
Trichomonas vaginalis and Candida albicans were identified by culture on the InPouch TV (Biomed Diagnostics) and Sabouraud's milieu, respectively. Bacterial vaginosis was diagnosed from Gram-stained vaginal smears with the use of the Nugent standardized scoring system, based on a weighted combination of different morphotypes: lactobacilli, Gardnerella vaginalis or bacteroides, and curved gram-variable rods.27
Study Outcomes
The primary study outcomes were the presence, frequency, and quantity of genital HIV-1 RNA during the treatment phase. Secondary outcomes included the presence and quantity of plasma HIV-1 RNA, as well as the detection of genital HSV-2 DNA and genital ulcers during the treatment phase.
Statistical Analysis
On the basis of data from a pilot study22 and a previous African study,7 we estimated that 150 women were required to detect a reduction of 0.4 log10 copy per milliliter of genital HIV-1 RNA between the two study groups, with an estimated variance of 0.5 and a power of 90%, with a 5% type I error. Our calculations allowed for a 15% loss to follow-up.
Analyses were conducted with Stata statistical software, version 9.0 (StataCorp) with the use of a modified intention-to-treat approach, in which the data for pregnant women were censored at the time of the first positive urine test. An a priori decision was made to adjust for the pre-randomization, baseline-phase genital HIV-1 RNA and HSV-2 DNA levels to allow for the variability of viral shedding for each of these outcomes respectively.28 A value equal to half the threshold was allocated to values below the threshold, including undetectable samples, and all viral loads were log10-transformed before analysis.
Primary analyses evaluated the effect per woman, using summary measures to combine the measurements for each woman into a single value. The effect on the presence of HIV-1 RNA or HSV-2 DNA at any time during the treatment phase (detection) was estimated as a risk ratio, using Poisson regression with robust standard errors,29 adjusted for the presence of the outcome measure during the baseline phase. The frequency of genital HIV-1 RNA and HSV-2 DNA (the proportion of visits during which the virus was detected, per woman) was estimated by a proportional-odds–ordered logistic-regression model adjusted for baseline frequency. Linear regression was used to compare the mean levels of genital or plasma HIV-1 RNA (in log10 copies per milliliter) between the study groups, adjusted for mean baseline values. Unadjusted measures of effect are also shown, and all reported P values are two-sided.
Further analyses were carried out on a per-visit basis with the use of repeated-measures analysis. Risk ratios were estimated by means of Poisson regression models fitted with generalized estimating equations with an exchangeable correlation matrix. The effect of the intervention on the presence of genital HIV-1 RNA and HSV-2 DNA was assessed by including an interaction term for the baseline or treatment phase and the study group. The trend of the treatment effect with time was evaluated by including an interaction term for study group and time. The effect of valacyclovir on the quantity of genital HIV-1 RNA was assessed with the use of random-effects linear regression among visits with detectable HIV-1 RNA only, owing to the high proportion of patients with no detectable shedding of the virus. The effect on the quantity of plasma HIV-1 RNA was assessed during all visits.
Results
Of 195 women who underwent screening, 150 were eligible to participate in the study; 148 were enrolled in the baseline phase of the study between August 2004 and January 2005. Of these, 140 women were randomly assigned to study groups, and 136 (68 in each group) were included in the analyses (Figure 1Figure 1
Enrollment and Outcomes.). The mean age of participants was 32 years (range, 16 to 50), the median CD4 cell count was 446 cells per cubic millimeter (interquartile range, 334 to 628), and the mean plasma HIV-1 RNA level was 4.44 log10 copies per milliliter (95% confidence interval [CI], 4.25 to 4.62) at enrollment. There were no major differences at enrollment between the study groups with regard to predefined demographic, behavioral, and clinical characteristics (Table 1Table 1
Characteristics of the Patients at Baseline.). However, the mean quantity of plasma HIV-1 RNA and the proportion of visits with detectable genital HIV-1 were higher in the placebo group during the entire baseline phase (Table 2Table 2
Analysis of Genital and Plasma HIV-1 RNA, Genital HSV-2 DNA, and Genital Ulcerations According to Study Phase and Group.).During the treatment phase, data from 11 women were censored (5 in the valacyclovir group and 6 in the placebo group) owing to pregnancy, dropout, or travel (Figure 1). Overall, of 408 possible visits, 376 (92.2%) were completed in the valacyclovir group and 374 (91.7%) in the placebo group. On the basis of the pill count, the average treatment compliance was 97.2% (95% CI, 94.0 to 100.0) in the valacyclovir group and 96.7% (95% CI, 94.6 to 98.9) in the placebo group. No serious adverse events or cases of hepatic or renal impairment associated with valacyclovir were reported, and the frequency of mild-to-moderate side effects was similar in the two groups (Table 3Table 3
Adverse Events.).As compared with women who never shed HSV-2 during the baseline phase, women with detectable HSV-2 DNA at least once during the baseline phase were found to have significantly higher mean viral loads (in log10 copies per milliliter) of genital HIV-1 RNA (3.04 for those with some HSV-2 shedding vs. 2.81 for those without shedding, P=0.05) and plasma HIV-1 RNA levels (4.75 for those with some HSV-2 shedding vs. 4.24 for those without shedding, P=0.001) during the baseline phase.
Effect of Treatment
Genital HIV-1 RNA
Valacyclovir had a nonsignificant effect on the proportion of women who had detectable HIV-1 RNA at least once (risk ratio, 0.93; 95% CI, 0.81 to 1.07). However, treatment was associated with a significant reduction in the frequency of genital HIV-1 RNA (odds ratio, 0.41; 95% CI, 0.21 to 0.80) (Table 2 and Figure 2Figure 2
Proportion of Women with Genital HIV-1 RNA According to Visit, Trial Phase, and Study Group.), adjusted for corresponding values in the baseline phase. In addition, the mean quantity of genital HIV-1 RNA was significantly lower in the valacyclovir group (mean reduction adjusted for baseline-phase values, −0.29 log10 copy per milliliter; 95% CI, −0.44 to −0.15; P<0.001).The repeated-measures analysis confirmed these results (Table 2) and found that the number of visits in which women had detectable genital HIV-1 RNA was significantly lower in the valacyclovir group (risk ratio, 0.77; 95% CI, 0.64 to 0.93; P=0.006). Further analyses showed an increase in treatment effect over time for both the presence of detectable genital HIV-1 RNA (risk ratio for every 2-week period during treatment phase, 0.93; 95% CI, 0.88 to 0.97; P=0.001) and the quantity of genital HIV-1 RNA (average reduction in mean quantity every 2 weeks during the treatment phase, 0.08 log10 copy per milliliter; 95% CI, 0.04 to 0.11; P<0.001) (Figure 2).
Plasma HIV-1 RNA
The mean quantity of plasma HIV-1 RNA among women in the valacyclovir group was significantly lower than in the placebo group (−0.53 log10 copy per milliliter; 95% CI, −0.72 to −0.35, adjusted for mean baseline-phase value; P<0.001). A similar result was found with the use of a repeated-measures analysis (Table 2). In addition, the treatment effect on plasma HIV-1 RNA increased with time (P<0.001), with an average reduction of 0.09 log10 copy per milliliter every 2 weeks (95% CI, 0.05 to 0.12; P<0.001).
Genital HSV-2 DNA
As expected, valacyclovir was highly effective in lowering the detection and frequency of genital HSV-2 DNA. Significantly fewer women in the valacyclovir group shed HSV-2 at all during the treatment phase: 19.1% in the valacyclovir group vs. 54.4% in the placebo group (risk ratio, 0.35; 95% CI, 0.21 to 0.60; P<0.001). In addition, the frequency of detection of genital HSV-2 DNA was strongly reduced in the valacyclovir group (odds ratio, 0.17; 95% CI, 0.07 to 0.38; P<0.001) (Table 2). Results were confirmed by repeated-measures analysis (Table 2). In a similar way, the proportion of women with at least one genital ulcer declined from baseline in the valacyclovir group, from 29.4% in the baseline phase to 4.4% in the treatment phase, as compared with no change in the placebo group (risk ratio, 0.16; 95% CI, 0.05 to 0.49; P=0.002).
Discussion
Daily treatment with valacyclovir for 3 months significantly diminished the shedding of HIV-1 RNA, reduced plasma HIV-1 RNA levels, and reduced genital HIV-1 RNA levels when shedding was present in women dually infected with HIV-1 and HSV-2. This effect steadily increased over time, which suggested that a longer duration of treatment might have led to an even greater reduction in HIV-1 RNA levels. These findings should be verified through clinical trials of longer duration. The effect of acyclovir on plasma HIV-1 RNA has been observed previously among 12 patients who were seropositive for HSV-2 and HIV-1.18 Acyclovir is unlikely to have a direct pharmacologic effect on HIV-1,30 and hence the most plausible explanation is that HSV suppressive therapy prevents clinical and subclinical reactivations responsible for an increased HIV-1 viral load. Indeed, HSV reactivation generates an influx of activated CD4+ T lymphocytes31 and significantly up-regulates HIV-1 replication.14-16,32 Transient HIV-1 systemic reactivation has been demonstrated during clinical HSV-2 episodes.17,18 In addition, subclinical HSV-2 episodes have been associated with mucosal disruption and lymphocytic infiltration similar to that found in clinical genital herpetic lesions,33 which suggests that asymptomatic HSV-2 shedding may act similarly and maintain HIV-1 replication at a high level. Data from our baseline phase support this hypothesis, with higher quantities of genital and plasma HIV-1 RNA among women shedding HSV-2.
Plasma HIV-1 RNA is the strongest predictor of genital HIV-1 RNA,34 although some compartmentalization of HIV-1 shedding may exist at the genital level.34-36 Thus, the effect of HSV suppressive therapy on HIV-1 shedding may simply be a consequence of a reduced systemic viral load. A complementary explanation would be that direct viral interaction occurs at the genital level. A trial of similar design conducted among women whose disease characteristics qualified them for HAART showed that valacyclovir could have a further effect on the residual shedding of HIV-1 despite good systemic control, which supports an effect of HSV-2 on independent mucosal HIV-1 replication.37
As expected, suppressive therapy with 500 mg of valacyclovir twice daily among women with HIV-1 infection proved very effective in reducing genital ulcerations and genital HSV-2 DNA. The effect on clinical episodes was similar to that reported in previous suppressive-treatment trials among coinfected women.38,39
Our study had several strengths, including a high level of compliance with study procedures and study drugs. Moreover, repeated-measures analysis of viral load allowed for adjustment for within-person variability of HSV-2 and HIV-1 shedding, as seen during the baseline phase.
Although our trial had no HIV clinical outcomes, its results may be relevant to HIV-1 prevention and management. It is estimated that a large proportion of persons who are seropositive for HIV-1 are also HSV-2 seropositive.7,40 The strong and significant reduction in plasma and genital HIV-1 RNA levels associated with valacyclovir treatment suggests that sustained forms of HSV-2 control (either antiviral therapy or effective vaccination) may reduce HIV-1 transmission, assuming that a reduction in genital and plasma HIV-1 RNA levels is a proxy for decreased transmissibility.19,41 This finding could be especially relevant among populations likely to play an important role in the dynamics of HIV transmission and among couples with discordant HIV status.19 At the individual level, the reduction in plasma HIV-1 RNA levels (with the likely reduction in CD4+ activation, which is responsible for T-lymphocyte depletion42) may lead to immunologic benefit over a longer duration of valacyclovir treatment, thereby slowing the course of HIV-1 disease. In addition to individual benefit regarding clinical recurrence, HSV suppressive therapy could also have an effect on HSV-2 transmission.43
The link between HSV-2 and HIV-1 should stimulate the development and evaluation of HSV-2 control methods. Several ongoing randomized, controlled trials will provide further evidence of the effect of HSV suppressive therapy on HIV-1 transmission and acquisition.19 Other trials are planned to evaluate the individual benefits, using immunologic and clinical outcomes. In particular, research to develop an HSV vaccine should rank high on the international research agenda for the prevention of HIV and HSV-2. Such a vaccine would represent a long-lasting form of HSV-2 control and possibly an important tool in HIV prevention.
Supported by the French Agence Nationale de Recherches sur le SIDA (ANRS, contract 2003-149).
Dr. Mayaud reports receiving research support from GlaxoSmithKline for other projects. No other potential conflict of interest relevant to this article was reported.
This article is dedicated to the memory of Laurence Vergne, who died tragically in January 2007.
We thank the women and the organizations for persons living with HIV/AIDS who participated in this study; the staff from Service d'Hygiene of Bobo-Dioulasso; Brigitte Bazin, Jean-François Delfraissy, and Michel Kazatchkine (of ANRS) for their constant support and encouragement; members of the data and safety monitoring committee, including chair Prof. Simon Cousens of the London School of Hygiene and Tropical Medicine, Prof. Adama Traoré of Centre Hospitalier Universitaire Ouagadougou in Burkina Faso, and Prof. Jean-Marie Huraux of Hôpital Pitié–Salpétrière in Paris; Rodolphe Thiebaut of INSERM E0338 Biostatistics in Bordeaux, France, and Profs. David Mabey and Richard Hayes of the London School of Hygiene and Tropical Medicine for their review of the manuscript; and the United Kingdom Department for International Development.
Source Information
From the Centre Muraz (N.N., A.O., I.K., L.V., M.-C.D., D.D., A. Sanon, R.V.) and University Hospital (J.-B.A., A. Sawadogo) — both in Bobo-Dioulasso, Burkina Faso; the London School of Hygiene and Tropical Medicine, London (N.N., H.A.W., P.M.); and Montpellier University Hospital and Research Unit 145, Montpellier, France (V.F., P.B., M.S., P.V.P.).
Address reprint requests to Dr. Nagot at the Clinical Research Unit, London School of Hygiene and Tropical Medicine, Keppel St., London WC1E 7HT, United Kingdom, or at n_nagot@hotmail.com.
Members of the Agence Nationale de Recherches sur le SIDA (ANRS) 1285 study group are listed in the Appendix.
Appendix
Investigators in the ANRS 1285 study group were as follows: Centre Muraz, Bobo-Dioulasso, Burkina Faso — E. Bahembera, A. Berthé, M. Coulibaly, M.-C. Defer, R. Diallo, D. Djagbaré, I. Konate, F. Ky-Dama, G.T. M'Boutiki, N. Meda, I. Millogo, N. Nagot, A. Ouédraogo, D. Ouedraogo, F. Rouet, A. Sanon, H. Sawadogo, R. Vallo, L. Vergne; London School of Hygiene and Tropical Medicine, London — P. Mayaud, N. Nagot, H.A. Weiss; Montpellier University Hospital and Research Unit 145, Institute for Research and Development and University of Montpellier 1, Montpellier, France — P. Becquart, V. Foulongne, M. Segondy, P. Van de Perre; University Hospital of Bobo-Dioulasso, Burkina Faso — J.-B. Andonaba, A. Sawadogo.
- References
References
1
Weiss H . Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11:Suppl 1:24A-35A
Medline2
Malkin JE . Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004;11:Suppl 1:2A-23A
Medline3
Corey L ,Wald A ,Celum CL ,Quinn TC . The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435-445
CrossRef | Web of Science | Medline4
Wald A ,Link K . Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52
CrossRef | Web of Science | Medline5
Herpes simplex virus type 2: programmatic and research priorities in developing countries. Report of a WHO/UNAIDS/LSHTM workshop (London, 14-16 February 2001). London: WHO/UNAIDS, 2001.
6
Freeman EE ,Weiss HA ,Glynn JR ,Cross PL ,Whitworth JA ,Hayes RJ . Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83
CrossRef | Web of Science | Medline7
Mbopi-Keou FX ,Gresenguet G ,Mayaud P , et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-1096
CrossRef | Web of Science | Medline8
McClelland RS ,Wang CC ,Overbaugh J , et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002;16:2425-2430
CrossRef | Web of Science | Medline9
Baeten JM ,McClelland RS ,Corey L , et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004;189:1466-1471
CrossRef | Web of Science | Medline10
Cowan FF ,Pascoe SJ ,Barlow KL , et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 2006;20:261-267
CrossRef | Web of Science | Medline11
Schacker T ,Ryncarz AJ ,Goddard J ,Diem K ,Shaughnessy M ,Corey L . Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-66
CrossRef | Web of Science | Medline12
Celum CL . The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004;11:Suppl 1:36A-45A
Medline13
Koelle DM ,Liu Z ,McClurkan CM , et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002;110:537-548
CrossRef | Web of Science | Medline14
Mosca JD ,Bednarik DP ,Raj NB , et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A 1987;84:7408-7412
CrossRef | Web of Science | Medline15
Margolis DM ,Rabson AB ,Straus SE ,Ostrove JM . Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992;186:788-791
CrossRef | Web of Science | Medline16
Golden MP ,Kim S ,Hammer SM , et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992;166:494-499
CrossRef | Web of Science | Medline17
Mole L ,Ripich S ,Margolis D ,Holodniy M . The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-770
CrossRef | Web of Science | Medline18
Schacker T ,Zeh J ,Hu H ,Shaughnessy M ,Corey L . Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-1725
CrossRef | Web of Science | Medline19
Celum CL ,Robinson NJ ,Cohen MS . Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;191:Suppl 1:S107-S114
CrossRef | Web of Science | Medline20
Safe and effective use of antiretroviral treatments in adults with particular reference to resource limited settings. Geneva: World Health Organization, 2000.
21
Nagot N ,Ouedraogo A ,Ouangre A , et al. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? J Acquir Immune Defic Syndr 2005;39:454-458
CrossRef | Web of Science | Medline22
Nagot N ,Foulongne V ,Becquart P , et al. Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women. J Acquir Immune Defic Syndr 2005;39:632-634
Web of Science | Medline23
Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO
Medline24
van Dyck E ,Buve A ,Weiss HA , et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004;42:2961-2965
CrossRef | Web of Science | Medline25
Rouet F ,Ekouevi DK ,Chaix ML , et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005;43:2709-2717
CrossRef | Web of Science | Medline26
Legoff J ,Bouhlal H ,Gresenguet G , et al. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol 2006;44:423-432
CrossRef | Web of Science | Medline27
Nugent RP ,Krohn MA ,Hillier SL . Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297-301
Web of Science | Medline28
Coombs RW ,Reichelderfer PS ,Landay AL . Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003;17:455-480
CrossRef | Web of Science | Medline29
Zou G . A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706
CrossRef | Web of Science | Medline30
Collier AC ,Schoenfeld D ,Hirsch M , et al. Lack of effect on survival of high-dose acyclovir and zidovudine compared with zidovudine alone for acquired immunodeficiency syndrome. Antiviral Ther 1998;3:25-32
Web of Science31
Cunningham AL ,Turner RR ,Miller AC ,Para MF ,Merigan TC . Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest 1985;75:226-233
CrossRef | Web of Science | Medline32
Fauci AS . The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-622
CrossRef | Web of Science | Medline33
Patel R ,Barton SE . Antiviral chemotherapy in genital herpes simplex virus infections. Int J STD AIDS 1995;6:320-328
Web of Science | Medline34
Kovacs A ,Wasserman SS ,Burns D , et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-1601[Erratum, Lancet 2002;359:630.]
CrossRef | Web of Science | Medline35
Philpott S ,Burger H ,Tsoukas C , et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol 2005;79:353-363
CrossRef | Web of Science | Medline36
Kemal KS ,Foley B ,Burger H , et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003;100:12972-12977
CrossRef | Web of Science | Medline37
Ouedraogo A ,Nagot N ,Vergne L , et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006;20:2305-2313
CrossRef | Web of Science | Medline38
DeJesus E ,Wald A ,Warren T , et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009-1016[Erratum, J Infect Dis 2003;188:1404.]
CrossRef | Web of Science | Medline39
Schacker T ,Hu HL ,Koelle DM , et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-28
Web of Science | Medline40
Smith JS ,Robinson NJ . Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002;186:Suppl 1:S3-S28
CrossRef | Web of Science | Medline41
Quinn TC ,Wawer MJ ,Sewankambo N , et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929
Full Text | Web of Science | Medline42
Grossman Z ,Meier-Schellersheim M ,Sousa AE ,Victorino RM ,Paul WE . CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002;8:319-323
CrossRef | Web of Science | Medline43
Corey L ,Wald A ,Patel R , et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20
Full Text | Web of Science | Medline
- Citing Articles (132)
Citing Articles
1
Nicholas J. Wagoner, Edward W. Hook. (2012) Herpes Diagnostic Tests and Their Use. Current Infectious Disease Reports
CrossRef2
Amanda J. Lee, Ali A. Ashkar. (2012) Herpes simplex virus-2 in the genital mucosa. Current Opinion in Infectious Diseases 25:1, 92-99
CrossRef3
A. L. Drake, A. C. Roxby, F. Ongecha-Owuor, J. Kiarie, G. John-Stewart, A. Wald, B. A. Richardson, J. Hitti, J. Overbaugh, S. Emery, C. Farquhar. (2012) Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. Journal of Infectious Diseases 205:3, 366-375
CrossRef4
Pragna Patel, Tim Bush, Kenneth H. Mayer, Sheila Desai, Keith Henry, Edgar Turner Overton, Lois Conley, John Hammer, John T. Brooks. (2012) Prevalence and Risk Factors Associated With Herpes Simplex Virus-2 Infection in a Contemporary Cohort of HIV-Infected Persons in the United States. Sexually Transmitted Diseases 39:2, 154-160
CrossRef5
Philippe Van de Perre, Nicolas Nagot. (2012) Herpes simplex virus: a new era?. The Lancet
CrossRef6
Arlene C. Sena, Peter Leone. (2012) Utility of Episodic Acyclovir Therapy for HSV-2 in Africa. Sexually Transmitted Diseases 39:1, 25-27
CrossRef7
C. Tanton, L. J. Abu-Raddad, H. A. Weiss. (2011) Time to Refocus on HSV Interventions for HIV Prevention?. Journal of Infectious Diseases 204:12, 1822-1826
CrossRef8
K. Mugwanya, J. M. Baeten, N. R. Mugo, E. Irungu, K. Ngure, C. Celum. (2011) High-dose Valacyclovir HSV-2 Suppression Results in Greater Reduction in Plasma HIV-1 Levels Compared With Standard Dose Acyclovir Among HIV-1/HSV-2 Coinfected Persons: A Randomized, Crossover Trial. Journal of Infectious Diseases 204:12, 1912-1917
CrossRef9
Nelly Mugo, Sufia S. Dadabhai, Rebecca Bunnell, John Williamson, Eddas Bennett, Isaack Baya, Nelly Akinyi, Ibrahim Mohamed, Reinhard Kaiser. (2011) Prevalence of Herpes Simplex Virus Type 2 Infection, Human Immunodeficiency Virus/Herpes Simplex Virus Type 2 Coinfection, and Associated Risk Factors in a National, Population-Based Survey in Kenya. Sexually Transmitted Diseases 38:11, 1059-1066
CrossRef10
Gina L. Westhoff, Sarah E. Little, Aaron B. Caughey. (2011) Herpes Simplex Virus and Pregnancy: A Review of the Management of Antenatal and Peripartum Herpes Infections. Obstetrical & Gynecological Survey 66:10, 629-638
CrossRef11
Pierre-Alain Rubbo, Edouard Tuaillon, Nicolas Nagot, Aziz Alami Chentoufi, Karine Bolloré, Jacques Reynes, Jean-Pierre Vendrell, Lbachir Benmohamed, Philippe Van De Perre. (2011) HIV-1 Infection Impairs HSV-Specific CD4+ and CD8+ T-Cell Response by Reducing Th1 Cytokines and CCR5 Ligand Secretion. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:1, 9-17
CrossRef12
Ruanne V. Barnabas, Emily L. Webb, Helen A. Weiss, Judith N. Wasserheit. (2011) The role of coinfections in HIV epidemic trajectory and positive prevention. AIDS 25:13, 1559-1573
CrossRef13
Richard A. Stein. (2011) Super-spreaders in infectious diseases. International Journal of Infectious Diseases 15:8, e510-e513
CrossRef14
Daniel D. Bohl, Kenneth A. Katz, Kyle Bernstein, Ernie Wong, Henry Fisher Raymond, Jeffrey D. Klausner, Willi McFarland. (2011) Prevalence and Correlates of Herpes Simplex Virus Type-2 Infection Among Men Who Have Sex With Men, San Francisco, 2008. Sexually Transmitted Diseases 38:7, 617-621
CrossRef15
Adrienne N. Poon, Zhijun Li, Ning Wang, Yan Hong. (2011) Review of HIV and other sexually transmitted infections among female sex workers in China. AIDS Care 23:sup1, 5-25
CrossRef16
Christina Ludema, Stephen R Cole, Charles Poole, Haitao Chu, Joseph J Eron. (2011) Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 25:10, 1265-1269
CrossRef17
Myron S. Cohen, Joseph J. Eron. (2011) Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the “Juice Worth the Squeeze?”. Sexually Transmitted Diseases 38:5, 410-412
CrossRef18
Amina A. Chaudhry, Gail Berkenblit, Allen L. Gifford, Joseph Cofrancesco, James Sosman, Lynn E. Sullivan. (2011) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 26:5, 538-542
CrossRef19
Julie Fox, Peter J White, Jonathan Weber, Geoff P Garnett, Helen Ward, Sarah Fidler. (2011) Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS 25:8, 1065-1082
CrossRef20
Peter Vickerman, Angela Devine, Anna M. Foss, Sinead Delany-Moretlwe, Philippe Mayaud, Gesine Meyer-Rath. (2011) The Cost-Effectiveness of Herpes Simplex Virus-2 Suppressive Therapy With Daily Aciclovir for Delaying HIV Disease Progression Among HIV-1-Infected Women in South Africa. Sexually Transmitted Diseases 38:5, 401-409
CrossRef21
J. M. Baeten, E. Kahle, J. R. Lingappa, R. W. Coombs, S. Delany-Moretlwe, E. Nakku-Joloba, N. R. Mugo, A. Wald, L. Corey, D. Donnell, M. S. Campbell, J. I. Mullins, C. Celum. (2011) Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. Science Translational Medicine 3:77, 77ra29-77ra29
CrossRef22
Gabriella d'Ettorre, Mirko Paiardini, Giancarlo Ceccarelli, Guido Silvestri, Vincenzo Vullo. (2011) HIV-Associated Immune Activation: From Bench to Bedside. AIDS Research and Human Retroviruses 27:4, 355-364
CrossRef23
Brian E Ng, Lisa M Butler, Tara Horvath, George W Rutherford, Lisa M Butler. 2011. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. .
CrossRef24
Samuel Biraro, Philippe Mayaud, Rhoda Ashley Morrow, Heiner Grosskurth, Helen A. Weiss. (2011) Performance of Commercial Herpes Simplex Virus Type-2 Antibody Tests Using Serum Samples From Sub-Saharan Africa: A Systematic Review and Meta-analysis. Sexually Transmitted Diseases 38:2, 140-147
CrossRef25
Chokechai Rongkavilit, Basim I. Asmar. (2011) Advances in Prevention of Mother-to-Child HIV Transmission: The International Perspectives. The Indian Journal of Pediatrics 78:2, 192-204
CrossRef26
Fati Kirakoya-Samadoulougou, Nicolas Nagot, Marie-Christine Defer, Seydou Yaro, Paulin Fao, François Ilboudo, Youssouf Langani, Nicolas Meda, Annie Robert. (2011) Epidemiology of Herpes Simplex Virus Type 2 Infection in Rural and Urban Burkina Faso. Sexually Transmitted Diseases 38:2, 117-123
CrossRef27
Charlotte Huet, Abdoulaye Ouedraogo, Issouf Konaté, Isidore Traore, François Rouet, Antoinette Kaboré, Anselme Sanon, Philippe Mayaud, Philippe Van de Perre, Nicolas Nagot. (2011) Long term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. BMC Public Health 11:1, 700
CrossRef28
H Burris, J Parkhurst, Y Adu-Sarkodie, P Mayaud. (2011) Getting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana. Health Research Policy and Systems 9:Suppl 1, S5
CrossRef29
Elena Sartori, Arianna Calistri, Cristiano Salata, Claudia Del Vecchio, Giorgio Palù, Cristina Parolin. (2011) Herpes simplex virus type 2 infection increases human immunodeficiency virus type 1 entry into human primary macrophages. Virology Journal 8:1, 166
CrossRef30
J. M. Baeten, J. Lingappa, I. Beck, L. M. Frenkel, G. Pepper, C. Celum, A. Wald, K. H. Fife, E. Were, N. Mugo, J. Sanchez, M. Essex, J. Makhema, J. Kiarie, C. Farquhar, L. Corey. (2011) Herpes Simplex Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir Does Not Select for Specific HIV-1 Resistance in HIV-1/HSV-2 Dually Infected Persons. Journal of Infectious Diseases 203:1, 117-121
CrossRef31
Sinead Delany-Moretlwe, Jonathan Stadler, Philippe Mayaud, Helen Rees. (2011) Investing in the future: lessons learnt from communicating the results of HSV/ HIV intervention trials in South Africa. Health Research Policy and Systems 9:Suppl 1, S8
CrossRef32
Dipankar Biswas, Biswajyoti Borkakoty, Jagadish Mahanta, Kamini Walia, Lahari Saikia, Brogen S Akoijam, Lobsang Jampa, Alia Kharkongar, Eric Zomawia. (2011) Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India. BMC Infectious Diseases 11:1, 325
CrossRef33
Misaki Wayengera. (2011) Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors. Theoretical Biology and Medical Modelling 8:1, 23
CrossRef34
Barb Lohman-Payne, Jennifer Slyker, Sarah L. Rowland-Jones. (2010) Immune-based Approaches to the Prevention of Mother-to-child Transmission of HIV-1: Active and Passive Immunization. Clinics in Perinatology 37:4, 787-805
CrossRef35
Jerome LeGoff, Clare Tanton, Constance Delaugerre, Helen A Weiss, John Changalucha, David A Ross, Kokugonza Mugeye, Laurent Belec, Richard J Hayes, Deborah Watson-Jones. (2010) No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 24:16, 2595-2596
CrossRef36
Richard Hayes, Deborah Watson-Jones, Connie Celum, Janneke van de Wijgert, Judith Wasserheit. (2010) Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?. AIDS 24:Suppl 4, S15-S26
CrossRef37
Nicholas Nguyen, Craig N. Burkhart, Craig G. Burkhart. (2010) Review: Identifying potential pitfalls in conventional herpes simplex virus management. International Journal of Dermatology 49:9, 987-993
CrossRef38
Kayvon Modjarrad, Sten H Vermund. (2010) Effect of treating co-infections on HIV-1 viral load: a systematic review. The Lancet Infectious Diseases 10:7, 455-463
CrossRef39
Rebecca F Baggaley, Christophe Fraser. (2010) Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Current Opinion in HIV and AIDS 5:4, 269-276
CrossRef40
Olamide Dosekun, Julie Fox. (2010) An overview of the relative risks of different sexual behaviours on HIV transmission. Current Opinion in HIV and AIDS 5:4, 291-297
CrossRef41
Allison E. Aiello, Amanda M. Simanek, Sandro Galea. (2010) Population Levels of Psychological Stress, Herpesvirus Reactivation and HIV. AIDS and Behavior 14:2, 308-317
CrossRef42
Kenneth H. Fife, James A. Williams, Allyson L. Thomas, Susan Ofner, Barry P. Katz, J. Dennis Fortenberry. (2010) Herpes Simplex Virus Type 2 Infection in Young Adult Women: Risk Factors for Infection and Frequency of Viral Shedding. Sexually Transmitted Diseases1
CrossRef43
Linn Elisabeth Lillerud, Vibeke Moerken Stuestoel, Ragnhild Elisabet Hoel, Zacharias Rukeba, Eyrun Floerecke Kjetland. (2010) Exploring the feasibility and possible efficacy of mass treatment and education of young females as schistosomiasis influences the HIV epidemic. Archives of Gynecology and Obstetrics 281:3, 455-460
CrossRef44
Darrell H.S. Tan, Sharon L. Walmsley. (2010) Response to Stegmann S, et al. [J. Clin. Virol. 47 (1) (2010) 79–81]. Journal of Clinical Virology 47:3, 297-298
CrossRef45
Jairam R Lingappa, Jared M Baeten, Anna Wald, James P Hughes, Katherine K Thomas, Andrew Mujugira, Nelly Mugo, Elizabeth A Bukusi, Craig R Cohen, Elly Katabira, Allan Ronald, James Kiarie, Carey Farquhar, Grace John Stewart, Joseph Makhema, Myron Essex, Edwin Were, Kenneth H Fife, Guy de Bruyn, Glenda E Gray, James A McIntyre, Rachel Manongi, Saidi Kapiga, David Coetzee, Susan Allen, Mubiana Inambao, Kayitesi Kayitenkore, Etienne Karita, William Kanweka, Sinead Delany, Helen Rees, Bellington Vwalika, Amalia S Magaret, Richard S Wang, Lara Kidoguchi, Linda Barnes, Renee Ridzon, Lawrence Corey, Connie Celum. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. The Lancet 375:9717, 824-833
CrossRef46
Anne Buvé, Lutgarde Lynen. (2010) Treating HIV infection with drugs for HSV-2 infection?. The Lancet 375:9717, 782-784
CrossRef47
Celum, C.Wald, A.Lingappa, J.R.Magaret, A.S.Wang, R.S.Mugo, N.Mujugira, A.Baeten, J.M.Mullins, J.I.Hughes, J.P.Bukusi, E.A.Cohen, C.R.Katabira, E.Ronald, A.Kiarie, J.Farquhar, C.Stewart, G.J.Makhema, J.Essex, M.Were, E.Fife, K.H.de Bruyn, G.Gray, G.E.McIntyre, J.A.Manongi, R.Kapiga, S.Coetzee, D.Allen, S.Inambao, M.Kayitenkore, K.Karita, E.Kanweka, W.Delany, S.Rees, H.Vwalika, B.Stevens, W.Campbell, M.S.Thomas, K.K.Coombs, R.W.Morrow, R.Whittington, W.L.H.McElrath, M.J.Barnes, L.Ridzon, R.Corey, L.. (2010) Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. New England Journal of Medicine 362:5, 427-439
Full Text48
Damjan S Nikolic, Vincent Piguet. (2010) Vaccines and Microbicides Preventing HIV-1, HSV-2, and HPV Mucosal Transmission. Journal of Investigative Dermatology 130:2, 352-361
CrossRef49
Brian R. Long, Ann E. Erickson, Joan M. Chapman, Jason D. Barbour, Bien-Aimee N. Vu, Emily L. Ho, Lewis L. Lanier, Mariana M. Sauer, Karina I. Carvalho, Douglas F. Nixon, Esper G. Kallas. (2010) Increased number and function of natural killer cells in human immunodeficiency virus 1-positive subjects co-infected with herpes simplex virus 2. Immunology 129:2, 186-196
CrossRef50
Peter C. Austin, Andrea Manca, Merrick Zwarenstein, David N. Juurlink, Matthew B. Stanbrook. (2010) A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 63:2, 142-153
CrossRef51
Gargi Dasgupta, Anthony B Nesburn, Steven L Wechsler, Lbachir BenMohamed. (2010) Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiology 5:1, 1-4
CrossRef52
Moira A McMahon, Janet D Siliciano, Rahul M Kohli, Robert F Siliciano. (2010) Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 24:2, 319-323
CrossRef53
Christophe Vanpouille, Andrea Lisco, Leonid Margolis. (2009) Acyclovir: a new use for an old drug. Current Opinion in Infectious Diseases 22:6, 583-587
CrossRef54
Moira A McMahon, Lin Shen, Robert F Siliciano. (2009) New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Current Opinion in Infectious Diseases 22:6, 574-582
CrossRef55
Amber Naresh, Richard Beigi, Laila Woc-Colburn, Robert A. Salata. (2009) The Bidirectional Interactions of Human Immunodeficiency Virus-1 and Sexually Transmitted Infections. Infectious Diseases in Clinical Practice 17:6, 362-373
CrossRef56
Joshua T. Schiffer, Lawrence Corey. (2009) New concepts in understanding genital herpes. Current Infectious Disease Reports 11:6, 457-464
CrossRef57
Andrea Lisco, Christophe Vanpouille, Leonid Margolis. (2009) A missed point in deciphering the viral synergy between herpes simplex virus and HIV. The Lancet Infectious Diseases 9:9, 522-523
CrossRef58
Ellen MacLachlan, Kenneth H Mayer, Ruanne Barnabas, Jorge Sanchez, Beryl Koblin, Ann Duerr. (2009) The Potential Role of Biomarkers in HIV Preventive Vaccine Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:5, 536-545
CrossRef59
Judith R Glynn, Samuel Biraro, Helen A Weiss. (2009) Herpes simplex virus type 2: a key role in HIV incidence. AIDS 23:12, 1595-1598
CrossRef60
Ronald H Gray. (2009) Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Current Opinion in HIV and AIDS 4:4, 274-278
CrossRef61
Aaron AR Tobian, Thomas C Quinn. (2009) Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Current Opinion in HIV and AIDS 4:4, 294-299
CrossRef62
Sarah S Wilson, Esra Fakioglu, Betsy C Herold. (2009) Novel approaches in fighting herpes simplex virus infections. Expert Review of Anti-infective Therapy 7:5, 559-568
CrossRef63
Rebecca F Baggaley, Jamie T Griffin, Ruth Chapman, T Déirdre Hollingsworth, Nicolas Nagot, Sinead Delany, Philippe Mayaud, Frank de Wolf, Christophe Fraser, Azra C Ghani, Helen A Weiss. (2009) Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load. AIDS 23:8, 1005-1013
CrossRef64
Antonio Volpi, Cesare Sarrecchia, Pasquale Sordillo. (2009) Aciclovir, herpes viruses and HIV: a never-ending story. Expert Review of Anti-infective Therapy 7:4, 403-407
CrossRef65
Scott Roberts. (2009) Herpes simplex virus: incidence of neonatal herpes simplex virus, maternal screening, management during pregnancy, and HIV. Current Opinion in Obstetrics and Gynecology 21:2, 124-130
CrossRef66
Anna M. Foss, Peter T. Vickerman, Zaid Chalabi, Philippe Mayaud, Michel Alary, Charlotte H. Watts. (2009) Dynamic Modeling of Herpes Simplex Virus Type-2 (HSV-2) Transmission: Issues in Structural Uncertainty. Bulletin of Mathematical Biology 71:3, 720-749
CrossRef67
SJ van Hal, DE Dwyer. 2009. Herpes Simplex: Viruses and Infections. .
CrossRef68
Barbara Romanowski, Linda N. Myziuk, Sharon L. Walmsley, Sylvie Trottier, Ameeta E. Singh, Stanley Houston, Mark Joffe, Isabelle Chiu. (2009) Seroprevalence and Risk Factors for Herpes Simplex Virus Infection in a Population of HIV-Infected Patients in Canada. Sexually Transmitted Diseases 36:3, 165-169
CrossRef69
Natasha L. Larke, Helen A. Weiss, Philippe Mayaud, Philippe Van de Perre, Tim Clayton, Abdoulaye Ouedraogo, Nicolas Nagot. (2009) Design of epidemiological studies measuring genital and plasma HIV-1 outcomes: lessons from a randomised controlled trial. Tropical Medicine & International Health 14:3, 267-275
CrossRef70
Haibo Wang, Ray Y. Chen, Guowei Ding, Yanling Ma, Jianguo Ma, Jin Hua Jiao, Zhenglai Wu, Gerald B. Sharp, Ning Wang. (2009) Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. International Journal of Infectious Diseases 13:2, 162-169
CrossRef71
Marina Mosunjac, Jaemin Park, Yun F. (Wayne) Wang, Talaat Tadros, Momin Siddiqui, Mahir Bagirov, James Little. (2009) Genital and Perianal Herpes Simplex Simulating Neoplasia in Patients with AIDS. AIDS Patient Care and STDs 23:3, 153-158
CrossRef72
Sinéad Delany-Moretlwe, Jairam R. Lingappa, Connie Celum. (2009) New insights on interactions between HIV-1 and HSV-2. Current Infectious Disease Reports 11:2, 135-142
CrossRef73
Richard A Zuckerman, Aldo Lucchetti, William LH Whittington, Jorge Sánchez, Robert W Coombs, Amalia Magaret, Anna Wald, Lawrence Corey, Connie Celum. (2009) HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 23:4, 479-483
CrossRef74
Sinéad Delany, Nonkululeko Mlaba, Tim Clayton, Godspower Akpomiemie, Alexio Capovilla, Jerome Legoff, Laurent Belec, Wendy Stevens, Helen Rees, Philippe Mayaud. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23:4, 461-469
CrossRef75
Philippe Van de Perre, Nicolas Nagot, Philippe Mayaud. (2009) Herpes simplex virus and HIV-1: deciphering viral synergy – Authors' reply. The Lancet Infectious Diseases 9:2, 74-75
CrossRef76
Elijah Paintsil, Warren A Andiman. (2009) Update on successes and challenges regarding mother-to-child transmission of HIV. Current Opinion in Pediatrics 21:1, 94-101
CrossRef77
Séverin-Guy Mahiane, Camille Legeai, Dirk Taljaard, Aurélien Latouche, Adrian Puren, Aurélie Peillon, Jean Bretagnolle, Pascale Lissouba, Eugène-Patrice Ndong Nguéma, Elisabeth Gassiat, Bertran Auvert. (2009) Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS 23:3, 377-383
CrossRef78
PD Griffiths. (2009) Treatment of herpesvirus cofactors?. Reviews in Medical Virology 19:1, 1-6
CrossRef79
Christophe Vanpouille, Andrea Lisco, Leonid Margolis. (2009) Off-label indication: acyclovir as an anti-HIV drug?. Future Virology 4:1, 1-5
CrossRef80
Kate Buchacz, Maria Rangel, Rachel Blacher, John T. Brooks. (2009) Changes in the clinical epidemiology of HIV infection in the United States: Implications for the clinician. Current Infectious Disease Reports 11:1, 75-83
CrossRef81
Jared M. Baeten, Lara B. Strick, Aldo Lucchetti, William L. H. Whittington, Jorge Sanchez, Robert W. Coombs, Amalia Magaret, Anna Wald, Lawrence Corey, Connie Celum. (2008) Herpes Simplex Virus (HSV)–Suppressive Therapy Decreases Plasma and Genital HIV‐1 Levels in HSV‐2/HIV‐1 Coinfected Women: A Randomized, Placebo‐Controlled, Cross‐Over Trial. The Journal of Infectious Diseases 198:12, 1804-1808
CrossRef82
Laila Darwich, Cecilia Cabrera, Joan Romeu, Javier Martinez-Picado, José A Esté, Cristina Tural, Rocio Bellido, Bonaventura Clotet, Ana Angulo, Lidia Ruiz, Margarita Bofill. (2008) The Magnitude of Interferon-γ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:5, 507-512
CrossRef83
Matthew F Chersich, Helen V Rees. (2008) Vulnerability of women in southern Africa to infection with HIV: biological determinants and priority health sector interventions. AIDS 22:Suppl 4, S27-S40
CrossRef84
Brenna L. Anderson, Susan Cu-Uvin. (2008) Determinants of HIV shedding in the lower genital tract of women. Current Infectious Disease Reports 10:6, 505-511
CrossRef85
Jared M. Baeten. (2008) New biomedical strategies for HIV-1 prevention in women. Current Infectious Disease Reports 10:6, 490-498
CrossRef86
Leigh F. Johnson, David A. Lewis. (2008) The Effect of Genital Tract Infections on HIV-1 Shedding in the Genital Tract: A Systematic Review and Meta-Analysis. Sexually Transmitted Diseases 35:11, 946-959
CrossRef87
Brenna L. Anderson, Chia‐Ching Wang, Allison K. DeLong, Tao Liu, Erna Milu Kojic, Jaclynn Kurpewski, Jessica Ingersoll, Kenneth Mayer, Angela M. Caliendo, Susan Cu‐Uvin. (2008) Genital Tract Leukocytes and Shedding of Genital HIV Type 1 RNA. Clinical Infectious Diseases 47:9, 1216-1221
CrossRef88
Gregory J. Mertz. (2008) Asymptomatic Shedding of Herpes Simplex Virus 1 and 2: Implications for Prevention of Transmission. The Journal of Infectious Diseases 198:8, 1098-1100
CrossRef89
Richard White, Connie Celum, Judith Wasserheit, Sevgi Aral, Richard Hayes. (2008) Control of sexually transmitted infections for HIV prevention. The Lancet 372:9646, 1297
CrossRef90
Kayvon Modjarrad, Eric Chamot, Sten H Vermund. (2008) Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 22:16, 2179-2185
CrossRef91
Eileen F Dunne, Sara Whitehead, Maya Sternberg, Sukhon Thepamnuay, Wanna Leelawiwat, Janet M McNicholl, Surin Sumanapun, Jordan W Tappero, Taweesap Siriprapasiri, Lauri Markowitz. (2008) Suppressive Acyclovir Therapy Reduces HIV Cervicovaginal Shedding in HIV- and HSV-2-Infected Women, Chiang Rai, Thailand. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:1, 77-83
CrossRef92
Andrea Lisco, Christophe Vanpouille, Egor P. Tchesnokov, Jean-Charles Grivel, Angélique Biancotto, Beda Brichacek, Julie Elliott, Emilie Fromentin, Robin Shattock, Peter Anton, Robert Gorelick, Jan Balzarini, Christopher McGuigan, Marco Derudas, Matthias Götte, Raymond F. Schinazi, Leonid Margolis. (2008) Acyclovir Is Activated into a HIV-1 Reverse Transcriptase Inhibitor in Herpesvirus-Infected Human Tissues. Cell Host & Microbe 4:3, 260-270
CrossRef93
François Rouet, Hervé Ménan, Johannes Viljoen, Nicole Ngo-Giang-Huong, Kishor Mandaliya, Diane Valéa, Truong Xuan Lien, Sivapragashini Danaviah, Dominique Rousset, Amandine Ganon, Eric Nerrienet. (2008) In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries. Expert Review of Molecular Diagnostics 8:5, 635-650
CrossRef94
José M. Miró. (2008) Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en el año 2008. Enfermedades Infecciosas y Microbiología Clínica 26:7, 437-464
CrossRef95
N. Kumarasamy, P. Balakrishnan, K.K. Venkatesh, A.K. Srikrishnan, A.J. Cecelia, E. Thamburaj, S. Solomon, K.H. Mayer. (2008) Prevalence and Incidence of Sexually Transmitted Infections among South Indians at Increased Risk of HIV Infection. AIDS Patient Care and STDs 22:8, 677-682
CrossRef96
Nancy S Padian, Anne Buvé, Jennifer Balkus, David Serwadda, Ward Cates. (2008) Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. The Lancet 372:9638, 585-599
CrossRef97
David M Butler, Davey M Smith, Edward R Cachay, George K Hightower, Charles Thomas Nugent, Douglas D Richman, Susan J Little. (2008) Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS 22:13, 1667-1671
CrossRef98
Philippe Van de Perre, Michel Segondy, Vincent Foulongne, Abdoulaye Ouedraogo, Issouf Konate, Jean-Marie Huraux, Philippe Mayaud, Nicolas Nagot. (2008) Herpes simplex virus and HIV-1: deciphering viral synergy. The Lancet Infectious Diseases 8:8, 490-497
CrossRef99
N. Nagot, A. Ouedraogo, I. Konate, H. A. Weiss, V. Foulongne, M. C. Defer, A. Sanon, P. Becquart, M. Segondy, A. Sawadogo, P. Van de Perre, P. Mayaud, . (2008) Roles of Clinical and Subclinical Reactivated Herpes Simplex Virus Type 2 Infection and Human Immunodeficiency Virus Type 1 (HIV‐1)–Induced Immunosuppression on Genital and Plasma HIV‐1 Levels. The Journal of Infectious Diseases 198:2, 241-9
CrossRef100
Soren Gantt, Jacquelyn Carlsson, Avinash K Shetty, Kristy D Seidel, Xuan Qin, Junior Mutsvangwa, Georgina Musingwini, Godfrey Woelk, Lynn S Zijenah, David A Katzenstein, Lisa M Frenkel. (2008) Cytomegalovirus and Epstein–Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis. AIDS 22:12, 1453-1460
CrossRef101
Elizabeth Griffin, Elizabeth Krantz, Stacy Selke, Meei-Li Huang, Anna Wald. (2008) Oral mucosal reactivation rates of herpesviruses among HIV-1 seropositive persons. Journal of Medical Virology 80:7, 1153-1159
CrossRef102
Daniel Podzamczer. (2008) Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Enfermedades Infecciosas y Microbiología Clínica 26:6, 356-379
CrossRef103
Sarah Hawkes. (2008) Addressing Sexually Transmitted Infections (STIs), including HIV/AIDS, in the Context of Sexual Health. International Journal of Sexual Health 20:1-2, 91-108
CrossRef104
Julia A. Schillinger, Christy M. McKinney, Renu Garg, R Charon Gwynn, Kellee White, Francis Lee, Susan Blank, Lorna Thorpe, Thomas Frieden. (2008) Seroprevalence of Herpes Simplex Virus Type 2 and Characteristics Associated With Undiagnosed Infection: New York City, 2004. Sexually Transmitted Diseases 35:6, 599-606
CrossRef105
Liesbeth JM Bollen, Sara J Whitehead, Philip A Mock, Wanna Leelawiwat, Suvanna Asavapiriyanont, Amphan Chalermchockchareonkit, Nirun Vanprapar, Tawee Chotpitayasunondh, Janet M McNicholl, Jordan W Tappero, Nathan Shaffer, Rutt Chuachoowong. (2008) Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?. AIDS 22:10, 1169-1176
CrossRef106
Connie Celum, Anna Wald, James Hughes, Jorge Sanchez, Stewart Reid, Sinead Delany-Moretlwe, Frances Cowan, Martin Casapia, Abner Ortiz, Jonathan Fuchs, Susan Buchbinder, Beryl Koblin, Sheryl Zwerski, Scott Rose, Jing Wang, Lawrence Corey. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. The Lancet 371:9630, 2109-2119
CrossRef107
Prameet M. Sheth, Sherzana Sunderji, Lucy Y. Y. Shin, Anuradha Rebbapragada, Sanja Huibner, Joshua Kimani, Kelly S. MacDonald, Elizabeth Ngugi, Job J. Bwayo, Stephen Moses, Colin Kovacs, Mona Loutfy, Rupert Kaul. (2008) Coinfection with Herpes Simplex Virus Type 2 Is Associated with Reduced HIV‐Specific T Cell Responses and Systemic Immune Activation. The Journal of Infectious Diseases 197:10, 1394-1401
CrossRef108
Laith J Abu-Raddad, Ira M Longini. (2008) No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 22:9, 1055-1061
CrossRef109
Watson-Jones, Deborah, Weiss, Helen A., Rusizoka, Mary, Changalucha, John, Baisley, Kathy, Mugeye, Kokugonza, Tanton, Clare, Ross, David, Everett, Dean, Clayton, Tim, Balira, Rebecca, Knight, Louise, Hambleton, Ian, Le Goff, Jerome, Belec, Laurent, Hayes, Richard, . (2008) Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania. New England Journal of Medicine 358:15, 1560-1571
Full Text110
Edward R Cachay, Simon D W Frost, Art F Y Poon, David Looney, Sherry M Rostami, Mary E Pacold, Douglas D Richman, Susan J Little, Davey M Smith. (2008) Herpes Simplex Virus Type 2 Acquisition During Recent HIV Infection Does Not Influence Plasma HIV Levels. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:5, 592-596
CrossRef111
Katherine T. Chen, Ruth E. Tuomala, Clara Chu, Meei-Li Huang, D. Heather Watts, Carmen D. Zorrilla, Mary Paul, Ron Hershow, Philip Larussa. (2008) No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. American Journal of Obstetrics and Gynecology 198:4, 399.e1-399.e5
CrossRef112
Richard Rupp, David I Bernstein. (2008) The potential impact of a prophylactic herpes simplex vaccine. Expert Opinion on Emerging Drugs 13:1, 41-52
CrossRef113
Valérie Martinez, Eric Caumes, Olivier Chosidow. (2008) Treatment to prevent recurrent genital herpes. Current Opinion in Infectious Diseases 21:1, 42-48
CrossRef114
David M. Koelle, Lawrence Corey. (2008) Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annual Review of Medicine 59:1, 381-395
CrossRef115
B.H. Thiers. (2008) Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus. Yearbook of Dermatology and Dermatologic Surgery 2008, 171-172
CrossRef116
Frances M Cowan, Jean H Humphrey, Robert Ntozini, Kuda Mutasa, Rhoda Morrow, Peter Iliff. (2008) Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 22:2, 193-201
CrossRef117
W. Lawrence Drew, Kim S. Erlich. 2008. Management of Herpesvirus Infections (Cytomegalovirus, Herpes Simplex Virus, and Varicella-Zoster Virus). , 437-461.
CrossRef118
R. Kaul, C. Pettengell, P.M. Sheth, S. Sunderji, A. Biringer, K. MacDonald, S. Walmsley, A. Rebbapragada. (2008) The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. Journal of Reproductive Immunology 77:1, 32-40
CrossRef119
H.F. Rabenau, H.W. Doerr. (2008) Genitaler Herpes und HSV-Transmission bei HIV-Patienten. Der Hautarzt 59:1, 11-17
CrossRef120
Nigel O'Farrell, Prashini Moodley, A Wim Sturm. (2007) Genital herpes in Africa: time to rethink treatment. The Lancet 370:9605, 2164-2166
CrossRef121
A. Rebbapragada, R. Kaul. (2007) More than their sum in your parts: the mechanisms that underpin the mutually advantageous relationship between HIV and sexually transmitted infections. Drug Discovery Today: Disease Mechanisms 4:4, 237-246
CrossRef122
Deborah Watson-Jones, Helen A Weiss, Mary Rusizoka, Kathy Baisley, Kokugonza Mugeye, John Changalucha, Dean Everett, Rebecca Balira, Louise Knight, David Ross, Richard J Hayes. (2007) Risk Factors for Herpes Simplex Virus Type 2 and HIV Among Women at High Risk in Northwestern Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:5, 631-642
CrossRef123
Richard J. Benjamin, Michael P. Busch, Chyang T. Fang, Edward P. Notari, Adrian Puren, Barry D. Schoub, Leslie H. Tobler, Wayne Hogrefe, Anthon du P. Heyns, Susan L. Stramer, Robert L. Crookes. (2007) Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion 0:0, 071117010348004-???
CrossRef124
Richard A. Zuckerman, Aldo Lucchetti, William L. H. Whittington, Jorge Sánchez, Robert W. Coombs, Rosario Zuñiga, Amalia S. Magaret, Anna Wald, Lawrence Corey, Connie Celum. (2007) Herpes Simplex Virus (HSV) Suppression with Valacyclovir Reduces Rectal and Blood Plasma HIV‐1 Levels in HIV‐1/HSV‐2–Seropositive Men: A Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial. The Journal of Infectious Diseases 196:10, 1500-1508
CrossRef125
Allison L. van Lint, Ernesto Torres-Lopez, David M. Knipe. (2007) Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368:2, 227-231
CrossRef126
Christopher S. Hall, Jeanne D. Marrazzo. (2007) Emerging issues in management of sexually transmitted diseases in HIV infection. Current Infectious Disease Reports 9:6, 518-530
CrossRef127
Vincent Soriano, Julie Sheldon, Pilar García-Gasco, Eugenia Vispo. (2007) Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses. AIDS 21:16, 2253-2254
CrossRef128
Gary R. West, Amy L. Corneli, Kim Best, Katie M. Kurkjian, William Cates Jr.. (2007) Focusing HIV Prevention on Those Most Likely to Transmit the Virus. AIDS Education and Prevention 19:4, 275-288
CrossRef129
Nicolas Nagot, Sinead Delany-Moretlwe, Philippe Mayaud. (2007) Antiherpetic therapy for HIV infection: linking prevention and care. Future HIV Therapy 1:2, 131-136
CrossRef130
(2007) HSV Therapy and HIV-1 Reduction. New England Journal of Medicine 356:22, 2323-2324
Full Text131
Corey, Lawrence, . (2007) Synergistic Copathogens — HIV-1 and HSV-2. New England Journal of Medicine 356:8, 854-856
Full Text132
Heidi Ledford. (2007) Treat herpes, treat HIV?. news@nature
CrossRef
- Letters
